Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

DAPA-CKD Trial Committees and Investigators, David C Wheeler*, Bergur V Stefánsson, Niels Jongs, Glenn M Chertow, Tom Greene, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, Robert D Toto, C David Sjöström, Anna Maria Langkilde, Hiddo J L Heerspink

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

383 Citations (Scopus)
3141 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science